When the injection is performed in a hospital outpatient department (POS 22) or emergency department (POS 23) , the facility bills for the injection administration under OPPS, and the physician does not separately report procedure code 96372
Instead, be thoughtful about your choices
The dosing schedule, titration timeline, and expected responses differ significantly
Some of those who have used injectable peptides unapproved for US sale from unregulated suppliers on the gray market have reported concerns, including unwanted changes to skin pigmentation, infection, swelling, pain, redness, and new or changing moles. Addressing safety concerns, the APC CEO reports that there has not been an uptick in adverse events reported through the FDAs adverse events reporting database related to injectable peptides